<DOC>
	<DOCNO>NCT00386321</DOCNO>
	<brief_summary>The purpose study determine whether treatment Yt90 Zevalin combination CHOP ( cyclophosphamide , doxorubicin , vincristine , prednisolone ) effective first line treatment patient bulky stage II stage III IV diffuse large B-cell lymphoma</brief_summary>
	<brief_title>Yt90 Zevalin Combination Chemotherapy ( Z-CHOP ) Treating Patients With Stage II , Stage III , Stage IV Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>Radioimmunotherapy represent significant advance unlabeled immunotherapy treatment patient B-cell non-Hodgkin 's lymphoma . The radiobiological effect associate Yt90-labelled ibritumomab tiuxetan ( Zevalin ) include induction apoptosis cell-cycle redistribution . The response rate tend high patient treat few prior therapy Yt90-labelled ibritumomab tiuxetan may suitable use early course therapy . Yt90-labelled ibritumomab tiuxetan less non hematologic toxicity chemotherapy , minimal alopecia , mucositis , nausea , vomiting , low incidence infection . Yt90-labelled ibritumomab tiuxetan regimen routinely safely give outpatient set complete 7-9 day thus convenient use .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm CD20 positive diffuse large Bcell lymphoma bulky stage II stage III stage IV Bidimensionally measurable disease Performance status Zubrod 02 Less 20,000/mcL circulate lymphoid cell WBC differential count No clinical evidence CNS involvement , prior diagnosis indolent lymphoma , histologic transformation Ejection fraction equal 45 % MUGA significant abnormality echocardiogram Fertile patient effective contraception method No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , stage I II cancer complete remission , carcinoma situ cervix No HIV positive , prior solid organ transplantation No prior antibody therapy , chemotherapy , radiotherapy lymphoma Serum creatinine ot bilirubin 2.5 X ULN unless due lymphoma Active uncontrolled infection Concurrent severe and/or uncontrolled medical disease could compromise participation study Patients 25 % infiltrated bone marrow Patients platelet count less 100,000/mcL neutrophil count less 1,500/mcL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Zevalin</keyword>
	<keyword>Zevalin plus CHOP</keyword>
	<keyword>Diffuse large B-cell lymphoma</keyword>
	<keyword>First line Diffuse large B-cell lymphoma</keyword>
</DOC>